Neglected disease, Rare disease, drug discovery, Donate Button iRND3 Home Page
Background large

Board of Directors

Picture of Ahvie Herskowitz

Ahvie Herskowitz
Chairman of the Board of Directors

Dr. Herskowitz is an academic clinician and scientist who spent the past 15 years in senior management positions at three large non-profit enterprises in the San Francisco Bay area. In 2000, he co-Founded the Institute for OneWorld Health, the first non-profit pharmaceutical company in the United States, dedicated to drug development for neglected infectious diseases in the developing world. In 2009, he was a leader in the start-up of Medicines360, a drug development organization dedicated to filling gaps in women's health globally. Dr. Herskowitz received his medical training at the Albert Einstein College of Medicine, and former Clinical Professor of Medicine at the University of California at San Francisco, is Founding Director of the Anatara Medicine, (, and currently on the Board of Directors for PVRI, Pulmonary Vascular Research Institute (

Picture of David Swinney

David C. Swinney
Chief Executive Officer

Dr. Swinney has over 25 years pharmaceutical experience. He currently is chief executive officer of iRND3. Dr. Swinney has devoted the majority of his career to analyzing and implementing drug discovery strategies that will increase the chance of success. These learnings are currently being practiced at iRND3. Dr. Swinney has a PhD in medicinal chemistry from the University of Washington and is author of over 100 publications in the fields of drug discovery, biochemistry and pharmacology.

Picture of Paul Nakagaki

Paul Nakagaki
Member of the Board of Directors

Dr. Nakagaki is the co-founder of TakeWing LLC, an innovation and strategy consultancy located in Switzerland. He has diverse experience in R&D strategy, portfolio management, project management and business development and led the restructuring of R&D for Roche Pharma. Dr. Nakagaki led the creation and implementation of successful Research and portfolio strategies as well as exploration of alternate external innovation models in R&D during his 25-year career at Roche. As a core member of international development project teams, Dr. Nakagaki led Chemistry, Manufacturing and Controls teams through approval of two globally marketed products, Cellcept TM and Toradol TM. He has a PhD in Chemistry from the University of Wisconsin.